推薦產品
product name
β-雌二醇 17-戊酸酯, ≥98%
生物源
synthetic
化驗
≥98%
形狀
powder
技術
ELISA: suitable
溶解度
acetone: 25 mg/mL, hazy, colorless
運輸包裝
ambient
儲存溫度
room temp
SMILES 字串
CCCCC(=O)OC1CCC2C3CCc4cc(O)ccc4C3CCC12C
InChI
1S/C23H32O3/c1-3-4-5-22(25)26-21-11-10-20-19-8-6-15-14-16(24)7-9-17(15)18(19)12-13-23(20,21)2/h7,9,14,18-21,24H,3-6,8,10-13H2,1-2H3
InChI 密鑰
RSEPBGGWRJCQGY-UHFFFAOYSA-N
尋找類似的產品？ 前往 產品比較指南
一般說明
β-Estradiol 17-valerate is a synthetic estrogen.
應用
β-Estradiol 17-valerate has been used:
- in an in-vivo assay, to synchronize the estrus cycle in athymic nude mice, to study the effect of recombinant pigment epithelium-derived factor (rPEDF) on induced ectopic fibroid lesions
- to study the influence of ovarian hormones on type II cGMP-dependent protein kinase (Prkg2) expression in mice
- to induce growth of estrogen-dependent tumor cells in athymic nude mice to establish a breast cancer mouse model
生化／生理作用
Estradiol valerate is observed to be useful for treating menopausal climacteric symptoms. β-Estradiol 17-valerate is used as a source of 17β-estradiol (E2) in in vitro fertilization, hormone replacement therapy, contraceptive drugs, to study reproductive disorders in animal models. It serves as growth promoter in animal farming. β-Estradiol 17-valerate is also used to culture single-sex population among fish. Studies in rats show that β-Estradiol 17-valerate has negative effects on the estrus cycle pattern.
訊號詞
Warning
危險分類
Aquatic Chronic 1 - Carc. 2 - Lact. - Repr. 2
儲存類別代碼
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
水污染物質分類（WGK）
WGK 3
個人防護裝備
Eyeshields, Gloves, type P3 (EN 143) respirator cartridges
分析證明 (COA)
輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號，寫有 ‘Lot’或‘Batch’.。
客戶也查看了
Kevin Hollevoet et al.
Oncotarget, 9(17), 13623-13636 (2018-03-24)
Antibody gene transfer presents an appealing alternative to conventional antibody protein therapy. This pre-clinical study evaluates the impact of various parameters on the pharmacokinetics and efficacy of in vivo expressed DNA-based anti-HER2 monoclonal antibodies (mAbs), newly engineered and delivered via
Huib A A M Van Vliet et al.
The Cochrane database of systematic reviews, (11)(11), CD009038-CD009038 (2011-11-11)
Quadriphasic oral contraceptives have been developed to reduce the adverse effects of oral contraceptives and are presented as more physiological since they mimic the natural cycle. However, suggested disadvantages of quadriphasic oral contraceptives include a possible increased risk of pill-taking
Christophe Blockeel et al.
Reproductive biomedicine online, 24(3), 272-280 (2012-02-03)
This randomized controlled trial analyses the ability to control the oocyte retrieval schedule of gonadotrophin-releasing hormone antagonist cycles through the administration of oestradiol valerate during the luteo-follicular transition period prior to the initiation of ovarian stimulation. Eighty-six women undergoing ovarian
Elizabeth Micks et al.
Women's health (London, England), 7(5), 513-524 (2011-09-02)
Estradiol valerate and dienogest have been combined to create a novel four-phasic oral contraceptive pill effective for both pregnancy prevention and treatment of heavy menstrual bleeding. This formulation represents the only oral contraceptive pill available in the USA containing an
Gonzalo Cruz et al.
Fertility and sterility, 98(5), 1283-1290 (2012-08-03)
To investigate the developmental window in which E(2) exposure produces irreversible changes in ovarian function resulting in polycystic ovary. Basic experimental study. University animal laboratory. Thirty Sprague-Dawley rats were administered a single E(2) valerate dose (10 mg/kg of weight) at
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務